A new phase 1 clinical trial has found that an emerging immunotherapy is promising for treating recurrent glioblastoma, a ...

One of the most exciting advances in cancer treatments in the past decade is the development of T cell immunotherapies, in which a patient's own immune system is trained to recognize and attack ...

Scientists have discovered that T cell receptors activate through a hidden spring-like motion that had never been seen before. This breakthrough may help explain why immunotherapy works for some ...

Much of the challenge in developing cancer therapies is determining methods to improve the effectiveness of the immune system’s ability to identify and kill cancer cells. While therapies like CAR T ...

Chemotherapy remains what many people picture when they hear a cancer diagnosis, but treatment for certain blood cancers now ...

Every time our body encounters a new disease-causing agent, a crucial defense system called adaptive immunity comes into play. T cells, the top agents in this system, survey the internal environment ...

Scientists at École Polytechnique Fédérale Lausanne (EPFL), and at UNIL-CHUV, University Hospital Lausanne (CHUV) and University of Lausanne (UNIL) have developed a computational method to create ...

As of April 2025, four CD19-directed chimeric antigen receptor (CAR)-T therapies and three CD20-targeting bispecific antibodies (BsAbs) have been US Food and Drug Administration (FDA) approved for the ...

The gray portion of this schematic represents a nanodisc, where for the first time researchers were able to replicate the native membrane environment (red dots) of a T-cell receptor (cyan). One of the ...